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Recent genome-wide association studies identified certain human leukocyote antigen (HLA) alleles as the
major risk factors of drug-induced liver injuries (DILI). While these alleles often cause large relative risk,
their predictive values are quite low due to low prevalence of idiosyncratic DILI. Finding additional risk
factors is important for precision medicine. However, optimal design of further genetic studies is hindered
by uncertain overall heritability of DILI. This is a common problem for low-prevalence pharmacological
traits, since it is difficult to obtain clinical outcome data in families. Herewe estimated the heritability (h2) of
DILI from case-control genome-wide single nucleotide polymorphism data using a method based on
random effect models.We estimated the proportion of h2 captured by common SNPs forDILI to be between
0.3 and 0.5. For co-amoxiclav induced DILI, chromosome 6 explained part of the heritability, indicating
additional contributions from common variants yet to be found. We performed simulations to assess the
robustness of the h2 estimate with limited sample size under low prevelance, a condition typical to studies on
idiosyncratic pharmacological traits. Our findings suggest that common variants outside of HLA contribute
to DILI susceptability; therefore, it is valuable to conduct further GWAS with expanded case collection.
G
iven the relatively small sample sizes obtainable in pharmacogenetic studies1, consortia are forming with
the goal of improving power to detect associations by pooling data generated frommultiple studies. One
effort relevant to this work is the International Serious Adverse Event Consortium (iSAEC). Phase 1 of
the project has resulted in one of the largest DILI research collections in the world and initial studies have
successfully identified genetic variants associated with DILI2.
While there are some successes identifying major risk factors of DILI (e.g., HLA-B*5701 as a major risk factor
of liver injury due to flucloxacillin), no SNPs were identified in DILI across all drugs, nor have any been validated
when flucloxacillin and coamoxiclav are excluded in this collection. This is likely due to limited power of detecting
modest SNP effects with the relatively small cohort size. Understanding the heritability of these conditions is one
step toward understanding genetic architecture of pharmacogenomic risk, andmay provide valuable information
for designing future studies.
Genome-wide association studies (GWAS) usually assume that common diseases are attributable to allelic
variants present in more than 1–5% of the population3. However, most variants identified so far in GWAS
analyses explain relatively small increases in risk. Also, in complex conditions where heritability has been
estimated through twin and family studies, GWAS have failed to produce findings to support estimations. For
example, the heritability of height is estimated to be 80%, however only 4% can be explained by variants identified
in GWAS studies4. This discrepancy has been described as the missing heritability problem5. Proposed explana-
tions for this issue are that rare variants with larger effects, gene-gene interactions, and/or gene-environment
interactions are poorly detected by GWAS approaches6. Another explanation for the missing heritability is that
common variants of smaller effect have not yet been identified. Peter Visscher’s group has developed the
Genome-wide Complex Trait Analysis (GCTA)method to measure the effect of common variants using a mixed
model with genome-wide SNP data7. Applying this approach has provided further evidence that a substantial
proportion of heritability is captured by common SNPs in complex traits including height and body mass index
(BMI).
This approach is particularly attractive to apply in the context of pharmacogenomics studies, where ascer-
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(ADRs) are subject to substantial genetic control in pharmacoge-
nomics studies, it is important to present evidence of the size of
the genetic component (or heritability) for the trait under
investigation.
Heritability estimates for complex traits are typically determined
through twin studies. However, these approaches have limited utility
in the context of susceptibility to ADRs8. Limitations are primarily
due to difficulties recruiting and obtaining clinical outcome data in
twins. This limitation might be overcome by applying the GCTA
approach that estimates the effect of common variants from gen-
ome-wide SNP data. In this studywe assessed the performance of this
approach with DILI GWAS datasets.
Results
Proportion of heritability captured by genome-wide common
variants for drug-induced liver injury. We estimated the
proportion of h2 captured by all genome-wide common SNPs,
chromosome 6 genome-wide SNPs and genome-wide SNPs
without chromosome 6 for DILI. Results for liver injuries induced
by co-amoxiclav and flucloxacillin are summarized in Table 1. We
observe that for flucloxacillin induced DILI patients, chromosome 6
explained almost all of the heritability (h2all 5 0.48 6 0.313, h2chr6 5
0.478 6 0.076, h2NOchr6 5 0.18 6 0.40). Whereas with co-amoxiclav
induced DILI patients, chromosome 6 explained part of the
heritability (h2all 5 0.40 6 0.16, h2chr6 5 0.17 6 0.041, h2NOchr6 5
0.378 6 0.17), indicating contributions from additional common
variants are yet to be found. Estimates for h2 may be
underestimated due to GCTA algorithm constraints so that SNP-
heritability on the observed scale could not be greater than 1. Even so,
this finding suggests that continuous collection of DILI cases is
valuable for the potential of discovering additional associations
with common genetic variants.
GCTA algorithm estimation of heritability for moderate sample
sizes.The heritability of T1D is estimated from pedigree studies to be
0.99,10. To date, the proportion of phenotypic variance explained by
validated SNPs and genome-wide significant variants (including pre-
GWAS loci with large effects) is 0.69,11. In addition, the proportion of
phenotypic variance explained when all GWAS SNPs are considered
simultaneously is 0.39,12.With the GCTA algorithm, we estimated the
proportion of phenotypic variance explained by all genome-wide
SNPs, chromosome 6 genome-wide SNPs, and genome-wide SNPs
without chromosome 6. Results of data for all WTCCC data are
summarized in Table 2. Results of data for 75 and 200 cases are
summarized in Table 3. Our simulations to assess of the impact of
sample sizes on heritability estimates indicated relatively stable
estimates with moderate sample sizes. We estimate the proportion
of h2 captured by common SNPs for T1D to be, on average, 0.51 6
0.23 with a sample size of 75 and 0.46 6 0.15 with a sample size of
200. These estimates are similar to estimations made with the entire
dataset of 1963 cases and 2938 controls (h2all50.44 6 0.037).
Moreover, estimates calculated from sample sizes of 75 and 200
cases gave similar results, with both indicating that chromosome 6
explains part of the heritability (the h2chr6 estimate is 0.196 0.15 with
75 cases and 0.12 6 0.058 with 200 cases). For a sample size of 75,
however, the standard deviation for our h2chr6 estimate is close to the
mean. This indicates that calculations are not stable with smaller
sample sizes, underscoring the uncertainty about flucloxacillin-
induced DILI. Estimates for h2chr6 calculated using this particular
T1D dataset may also be underestimated due to inadequate SNP
density in the MHC region in this particular data set.
Analysis of measurement errors in the drug-induced liver injury
dataset. Lastly, we observe that the estimated h2 is 0 for both
flucloxacillin induced and co-amoxiclav induced DILI controls
coded as cases. Results are summarized in Table 4. We conclude
that there were no substantial measurement errors in our datasets.
Discussion
While further investigation is required to confirm the robustness of
the GCTA algorithm for low prevalence traits such as DILI, this work
highlights the potential value of its application. Here we were able to
apply the algorithm to investigate the contribution of common var-
iants on the chromosome level. Such investigations can provide
insight into disease mechanism and into inter-individual variation.
Moreover, for ADRs in particular, we are able to provide previously
unobtainable estimates of heritability. Such estimates will help
optimize designs of future studies for identifying additional genetic
contributions to these conditions.
Findings suggest that collecting and genotyping more co-amoxi-
clav induced DILI cases is valuable for discovering additional asso-
ciations. While further investigation is required to confirm the
robustness of the GCTA algorithm for low prevalence traits like
DILI, this work highlights the potential value of its application.
Table 1 | Heritability estimates from iSAEC genome-wide data for co-amoxiclav and flucloxacilin induced drug-induced liver injury
Drug (population) Prevalence No. cases No. controls Estimated h2all (SE) Estimated h2chr6 (SE) Estimated h2NOchr6 (SE)
co-amoxiclav 0.0005 201 532 0.40 (0.16) 0.17 (0.041) 0.38 (0.17)
flucloxacillin 0.0005 77 288 0.48 (0.32) 0.48 (0.076) 0.18 (0.40)
co-amoxiclav 0.0001 201 532 0.26 (0.10) 0.11 (0.027) 0.25 (0.11)
flucloxacillin 0.0001 77 288 0.31 (0.21) 0.31 (0.05) 0.12 (0.26)
Table 2 | Heritability estimates from WTCCC genome-wide data for T1D
T1D Prevalence No. cases No. controls Estimated h2all (SE) Estimated h2chr6 (SE) Estimated h2NOchr6 (SE)
0.0005 1963 2938 0.26 (0.022) 0.068 (0.008) 0.22 (0.022)
0.008 1963 2938 0.434 (0.037) 0.11 (0.014) 0.37 (0.037)
Table 3 | Heritability estimation from WTCCC genome-wide data for T1D with limited number of samples
T1D Prevalence No. Cases No. Controls Estimated h2all (SD) Estimated h2chr6 (SD) Estimated h2NOchr6 (SD)
0.008 75 225 0.51 (0.23) 0.19 (0.15) 0.28 (0.31)
0.008 200 600 0.46 (0.18) 0.12 (0.058) 0.35 (0.16)
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Particularly for pharmacological traits, we can provide previously
unobtainable estimates of heritability. Such estimates will help
optimize designs for future studies.
Methods
Study population.DILI datasets were from case-control studies of individuals taking
flucloxacillin (77 cases and 288 population controls)2 and individuals taking co-
amoxiclav (201 cases and 532 population controls)13. The genotyping data were
generated using the Illumina 1M-duo described previously2,13.
Genome-wide complex trait analysis algorithm.TheGCTA algorithmmeasures the
effect of common variants with genome-wide SNP data using a mixed model
approach7. The algorithm involves first estimating the genetic relationship matrix
(GRM) of all individuals, then fitting the GRM in a mixed linear model (MLM) for
binary traits to estimate the proportion of variance explained by all the autosomal
SNPs. We used GCTA algorithm extended for case-control designs14 to estimate h2
captured by common SNPs for DILI. We also assessed the robustness of the GCTA
algorithm with datasets of moderate sample sizes and low prevalence.
Estimating proportion of heritability captured by common variants.We used the
GCTA algorithm to estimate h2 from iSAEC DILI genome-wide data (all
chromosomes), chromosome 6 data, and genome-wide data without chromosome 6.
We also estimated h2 for all individuals (co-amoxiclav or flucloxacillin inducedDILI),
for individuals with co-amoxiclav induced DILI, and for individuals with
flucloxacillin induced DILI. For individuals with co-amoxiclav induced DILI we
evaluated northwest Europeans only and southern Europeans both together and
separately. All analyses were performed separately. For each population and dataset,
unless otherwise noted, we calculated h2 adjusting for prediction errors due to global
structure and local structure.We used principal components analysis (PCA) to adjust
for prediction errors due to global structure. Two principal components were
included as regression covariates in the mixed model. We also used an optional
functionality of theGCTA tool to adjust for prediction errors due to imperfect linkage
disequilibrium. All analyses were performed for DILI prevalence estimated to be
0.00012,15 and 0.0005.We reportedmain results using a prevalence of 0.0005 based on
recent work (the estimated rate is 0.00043 in Iceland population16) and a general trend
of underreporting of DILI incidences17.
Assessing the robustness of the GCTA algorithm with moderate sample sizes. To
evaluate the robustness of the GCTA algorithm with datasets of moderate sample
sizes, we conducted a positive control and negative control experiment. We
performed simulations for our positive control experiment. Simulations involved
estimating h2 for subsets of cases and controls from a Type I Diabetes (T1D) dataset.
We choose to use a T1D because the histocompatibility complex (MHC) region on
chromosome 6 has major genetic contribution to risks of both DILI2 and T1D11,18.
Specifically, we used the Welcome Trust Case Control Consortium (WTCCC) T1D
dataset (1963 cases and 2938 controls)18. Genotyping was conducted for theWTCCC
study using an Illumina 550K chip. We estimated h2 from genome-wide data (all
chromosomes), chromosome 6 data, and genome-wide data without chromosome 6
for cases and controls with a 153 ratio, where the number of cases were 75 and 200 to
reflect sample sizes similar to iSAECDILI sample sizes. Estimates for h2were averaged
over twenty random selections of cases and controls for these sample sizes. The
prevalence of T1D is estimated to be 0.00819. We report the mean and standard
deviation of the twenty h2 estimates. We also report h2 estimates and standard errors
with the full WTCCC T1D dataset and the GCTA parameter for prevalence set at
0.0005 and 0.008. Given the WTCCC data were collected from a homogenous
population, however, we do not adjust for prediction errors due to global structure.
For a negative control experiment we tested for measurement errors by estimating
h2 for DILI controls coded as cases with WTCCC controls. This analysis was per-
formed with northwestern European controls from the flucloxacillinin induced and
co-amoxiclav induced DILI datasets. The prevalence of DILI was set to be 0.0005.
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Table 4 | Heritability estimation to assess measurement errors
DILI indicated drug (population) No. cases No. controls Estimated h2all (SE)
flucloxacillin 288 (controls coded as cases) 864 (WTCCC controls) 0.0 (0.11)
co-amoxiclav 306 (controls coded as cases) 918 (WTCCC controls) 0.0 (0.11)
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